Combined therapeutic application of botulinum toxin type A. low-frequency rTMS,andIntensive occupational therapy for post-stroke spastic upper limb hemiparesis

European Journal of Physical and Rehabilitation Medicine

Volumn 48, Issue 1, 2012, Pages 47-55

  Kakuda, W ^a   Abo, M ^a   Momosaki, R ^a   Yokoi, A ^a   Fukuda, A ^a   Ito, H ^a   Tominaga, A ^a   Umemori, T ^a   Kameda, Y ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Muscle spasticity; Rehabilitation paresis; Stroke; Transcranial magnetic stimulation

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARM; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; OCCUPATIONAL THERAPY; PARESIS; RETROSPECTIVE STUDY; SPASTICITY; TIME; TRANSCRANIAL MAGNETIC STIMULATION;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; OCCUPATIONAL THERAPY; PARESIS; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION; UPPER EXTREMITY;

EID: 84862549621     PISSN: 19739087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008;15:533-9. (Pubitemid 351677501)
2. Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and healthrelated quality of life 18 months after stroke. Cerebrovasc Dis 2006;21:247-53.
3. Smania N, Picelli A, Munari D, Geroin C, lanes P, Waldner A et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 2010;46:423-8.
4. Simpson DM, Alexander DN, O'Brien CF, Taqliati M, Asward AS, Leon JM et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10. (Pubitemid 26159292)
5. Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
6. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M et al. Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400. (Pubitemid 34851831)
7. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-9. (Pubitemid 38962361)
8. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010;46:401-10.
9. Mansur CG, Fregni F, Boggio PS, Riberto M, Gallucci-Neto J, Santos CM et al. A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients. Neurology 2005;64:1802-4. (Pubitemid 40695826)
10. Takeuchi N, Chuma T, Matsuo Y, Watanabe I, Ikoma K. Repetitive transcranial magnetic stimulation of contralesional primary motor cortex improves hand function after stroke. Stroke 2005;36:2681-6.
11. Fregni F, Boggio PS, Valle AC, Rocha RR, Duarte J, Ferreira MJ et ai. A sham-controlled trial of a 5-day course of repetitive transcranial magnetic stimulation of the unaffected hemisphere in stroke patients. Stroke 2006;37:2115-22. (Pubitemid 44309913)
12. Van der Lee JH, Wagenaar RC, Lankhorst GJ, Vogelaar TW, Deville WL, Bouter LM. Forced use of the upper extremity in chronic stroke patients: results from a single-blind randomized clinical trial. Stroke 1999;30:2369-75. (Pubitemid 29517737)
13. Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 2006;296:2095-104. (Pubitemid 44664704)
14. Corbetta D, Sirtori V, Moja L, Gatti R. Constraint-induced movement therapy in stroke patients: systematic review and metaanalysis. Eur J Phys Rehabil Med 2010;46:537-44.
15. Conchou F, Loubinoux I, Castel-Lacanal E, Le Tinnier A, Gerdelat-Mas A, Faure-Marie N et al. Neural substrates of lowfrequency repetitive transcranial magnetic stimulation during movement in healthy subjects and acute stroke patients. A PET study. Hum Brain Mapp 2009;30:2542-57.
16. Lewy CE, Nichols DS, Schmalbrock PM, Keller P, Chakeres DW. Functional MRI evidence of cortical reorganization in upperlimb stroke hemiplegia treated with constraint-induced movement therapy. AmJ Phys Med Rehabil 2001;80:4-12. (Pubitemid 32038009)
17. Kakuda W, Abo M, Kobayashi K, Momosaki R, Yokoi A, Fukuda A et al. Low-frequency rTMS and intensive occupational therapy for post-stroke patients with upper limb hemiparesis: A preliminary study of 15-day protocol. Int J Rehabil Res 2010;33:339-45.
18. Kakuda W, Abo M, Kobayashi K, Takagishi T, Momosaki R, Yokoi A et al. Fukuda. Baseline severity of upper limb hemiparesis influences the outcome of low-frequency rTMS combined with intensive occupational therapy in patients who have had a stroke. PMR 2011;3:516-22.
19. Shaw LC, Price CIM, van Wijck FMJ, Shackley P, Steen N, Barnes MP et al. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke 2011;42:1371-9.
20. Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Com-bined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: A randomized controlled study. Neurorehabil Neural Repair 2010;24:34-41.
21. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: Report and suggested guidelines from the international workshop on the safety of repetitive transcranial magnetic stimulation, June 5-7, 1990. Electroencephalogr Clin Neurophysiol 1998;108:1-16.
22. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 1997;6:S208-220. (Pubitemid 128753048)
23. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010;26:1983-92.
24. Gladstone DJ, Danells CJ, Black SE. The Fugl-Meyer assessment of motor recovery after stroke: a critical review of its measurement properties. Neurorehabil Neural Repair 2002; 16: 232-40. (Pubitemid 34984898)
25. Morris DM, Uswatte G, Crago JE, Cook EW LU, Taub E. The reliability of the wolf motor function test for assessing upper extremity function after stroke. Arch Phys Med Rehabil 2001;82:750-5. (Pubitemid 32520783)
26. van der Lee J, Beckerman H, Knol D, de Vet H, Bouter I. Clinimetric properties of the motor activity log for the assessment of arm use in hemiparetic patients. Stroke 2004;35:1-5.
27. Gregson JM, I.eathley M, Moore AP, Sharma AK, Smith TL, Watkins CL. Reliability of the tone assessment scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. Arch Phys Med Rehabil 1999;80:1013-6. (Pubitemid 29439312)
28. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measure of spasticity. Clin Rehabil 1999;13:373-83. (Pubitemid 29425632)
29. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-8. (Pubitemid 351644137)
30. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Leieune TM et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25.
31. Lin KC, Hsieh YW, Wu CY, Chen CL, Jang Y, Liu JS. Minimal detectable change and clinically important difference of the Wolf Motor Function Test in stroke patients. Neurorehabil Neural Repair 2009;23:429-34.
32. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-61. (Pubitemid 39430607)
33. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799-806. (Pubitemid 351602250)
34. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med 2005;37:252-7. (Pubitemid 41025335)